Gavi, the Vaccine Alliance, has lauded the rollout of malaria vaccines across Africa as the fastest in its history, marking a pivotal moment in the battle against one of the continent's most devastating diseases. Currently, 25 African countries have successfully integrated malaria vaccines into their routine immunization programmes with crucial support from Gavi. Initial reports from these countries indicate a significant positive impact, including a reduction in severe diseases, hospital admissions, and ultimately, lives saved. However, as the rollout continues to expand, critical questions regarding its long-term impact, efficient delivery mechanisms, and the sustainability of progress remain at the forefront.

Thabani Maphosa, Gavi's Chief Country Delivery Officer, provided insights into how this rapid deployment of malaria vaccines is transforming malaria control efforts, highlighting the delivery challenges countries face and the essential elements required to maintain momentum. Malaria continues to be a leading cause of illness and death in Africa, disproportionately affecting children under five, who account for over 75% of global malaria fatalities. The continent bears an overwhelming share of this global burden. Maphosa emphasized that the routine, large-scale delivery of malaria vaccines, alongside established tools like bed nets, chemoprevention, and treatment, represents a critical turning point. While this does not imply immediate elimination, it signifies that countries are now better equipped to protect children and alleviate pressure on their healthcare systems.

The unprecedented speed of the vaccine rollout across 25 countries is a direct reflection of the immense demand from these nations. Gavi anticipated this high demand and dedicated significant time to planning for the vaccine's availability and subsequent deployment. Strong partnerships have been instrumental in this process, enabling governments, with Gavi's and its partners' support, to integrate the complex four-dose vaccination programme into existing immunization systems, even in fragile and high-burden settings.

Early data strongly suggest that malaria vaccines, when layered on top of other interventions, significantly contribute to improved outcomes. Reports from countries such as Kenya, Malawi, Ghana, and Cameroon demonstrate reductions in severe disease and hospital admissions among vaccinated children, corroborating findings from earlier pilot programmes. A notable example is Burkina Faso, where nationwide malaria vaccination, implemented concurrently with bed nets, seasonal chemoprevention, and community mobilization, led to a 32% decline in reported malaria cases between 2024 and 2025, with malaria-related child deaths nearly halved. This evidence underscores the transformative potential of vaccines delivered at scale within robust national programmes.

Scaling up malaria vaccination across Africa has presented unique challenges, particularly concerning the delivery of all four recommended doses. While the first three doses are administered in quick succession, the fourth dose requires a later follow-up, necessitating tailored strategies. Countries, starting from diverse baselines in routine immunization coverage and health system capacity, have responded by adopting step-by-step phased approaches, testing context-specific delivery methods. Gavi has further supported these efforts by investing US$5 million in a learning agenda across seven African countries. This initiative aims to generate evidence on the most effective strategies for delivering the crucial fourth dose and seamlessly integrating malaria vaccination into existing malaria control programmes, immunization initiatives, and primary healthcare infrastructure. A clear lesson emerging is that the most successful countries combine vaccines with other proven interventions and customize delivery to their specific epidemiological contexts, supported by strong coordination between malaria and immunization programmes, reliable surveillance, and sustained community engagement.

Climate change is increasingly altering malaria transmission patterns. Rising temperatures, increased flooding, and erratic rainfall create new breeding grounds for mosquitoes and disrupt established control efforts. Several countries are experiencing sharp increases in malaria cases linked to extreme weather events, highlighting the growing volatility of malaria transmission. This makes sustained prevention more critical than ever, with vaccines adding an essential layer of protection for young children as malaria patterns become less predictable.

Top priorities for malaria funding and research and development (R&D) are multifaceted. Firstly, it is imperative to protect the current momentum. Gavi aims to support countries in fully protecting 50 million more children with the malaria vaccine over the next five years, preventing 180,000 deaths. Achieving this requires the full funding of Gavi's strategy and increased investment from countries themselves. Secondly, sustaining investment in integrated malaria programmes—combining vaccines, chemoprevention, vector control, diagnostics, and treatment—is equally critical; withdrawing funding now risks reversing the gains being made. Lastly, continued R&D is vital. The two WHO-prequalified